TQB2930

TQB2930 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical and Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are HER2 and EGFR (the sponsor names HER2). The sponsor states: TQB2930 is a HER2 bispecific antibody given by intravenous infusion, being studied as monotherapy or combination therapy in HER2-positive recurrent/metastatic breast cancer. ClinicalTrials.gov describes the intervention as: TQB2930 for injection is a HER2 bispecific antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer. The largest, NCT07512583, plans to enrol 178 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.